You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
興齊眼藥(300573.SZ)擬在河南及上海兩地分別設立全資子公司 進一步豐富產品管線
格隆匯 12-09 15:59

格隆匯12月9日丨興齊眼藥(300573.SZ)公佈,公司第三屆董事會第十五次會議審議通過了《關於設立兩家全資子公司的議案》。基於公司戰略發展需要,為加快產業佈局,進一步豐富產品管線,增強公司的綜合競爭力,公司在河南、上海兩地分別設立全資子公司,河南子公司的註冊資本為人民幣1000萬元,上海子公司的註冊資本為人民幣3000萬元。具體以最終公司登記機關核准的內容為準。

河南興齊眼藥科技有限公司及上海康恩德醫療科技有限公司經營範圍:藥品研發;藥品技術開發、技術諮詢、技術推廣、技術轉讓;I、II、III類醫療器械、滴眼劑(含激素類)、溶液劑(眼用)生產。

此次投資目的為基於公司戰略發展需要,為加快產業佈局,進一步豐富產品管線,增強公司的綜合競爭力,公司在河南、上海兩地分別設立全資子公司,推動公司新產品上市進程,實現成果轉化,增強公司的綜合競爭力。

此次以自有資金投資設立兩家子公司,若投資未達到預期效果,將會對公司的現金使用效率、財務及經營狀況產生一定的影響;此次投資為公司整體戰略佈局的一部分,不存在損害公司及全體股東利益的情形。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account